Compare Dover Corp (DOV) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Cassava Sciences Inc — how do they compare? Dover Corp trades at $190.16 (market cap $25.45B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Dover Corp is far larger — about 645.9× Cassava Sciences Inc's market cap, and Dover Corp pays a 1.11% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and Cassava Sciences Inc for 37 Days on average.
| DOV | FLNA | |
|---|---|---|
Market Cap | $25.45B | $39.40M |
Volume | 661,758 | 759,018 |
Sector | Industrials | Health |
52-Week High | $233.31 | $4.64 |
52-Week Low | $161.16 | $0.68 |
Typical Hold Time | 73 Days | 37 Days |
Enterprise Value | $26.95B | -$43.28M |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $188.29, down 1.87% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 13.48% net income margin and has beaten earnings expectations for three consecutive quarters. Recent acquisitions and product launches demonstrate ongoing business development. Analyst consensus remains strongly bullish with a $243.20 price target representing 29% upside potential.
The stock offers attractive upside based on analyst targets and consistent earnings performance, though technical indicators suggest near-term pressure. Key risks include market volatility and integration challenges from recent acquisitions. The company's Dividend King status and strong cash flow generation provide stability for long-term investors.
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
